Realm Therapeutics Announces Completion of $26 million Private Placement

Realm Therapeutics plc (AIM: RLM) has announced the private placement of $26 million, previously disclosed September 21, was approved by its shareholders at a general meeting in London on October 9.
As quoted in the press release:

The 66,396,485 new ordinary shares issued by the Company in the PIPE were admitted to trading on AIM, a market operated by the London Stock Exchange, on October 10, 2017. US and UK healthcare specialist funds that participated in the PIPE included OrbiMed, BVF Partners LP, RA Capital Management, Abingworth BioEquities Master Fund Ltd and Polar Capital.

Enquiries:
Realm Therapeutics plc	+44 (0) 20 3727 1000
Alex Martin, Chief Executive Officer
Marella Thorell, Chief Financial Officer and Chief Operating Officer
FTI Consulting	+44 (0) 20 3727 1000
Simon Conway / Mo Noonan
N+1 Singer (Nominated Adviser and Broker)	+44 (0) 20 7496 3000
Aubrey Powell / Lauren Kettle

Click here to read the full press release.